FDA Expands Agilent's PD-L1 Test Indication for Keytruda Use
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2026
0mins
Source: seekingalpha
- Indication Expansion: The FDA has expanded the indication for Agilent's PD-L1 IHC 22C3 pharmDx test to include four new tumor types, such as esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction adenocarcinoma, enhancing the test's value in cancer treatment decision-making.
- Market Impact: This expansion allows the PD-L1 IHC 22C3 pharmDx test to assist more patients in accessing Merck's Keytruda (pembrolizumab) treatment, which is expected to boost Agilent's competitiveness in the cancer diagnostics market, particularly in the rapidly growing immunotherapy sector.
- Technical Platform: The test is performed on the Dako Omnis platform, integrating advanced detection technology that ensures accuracy and reliability of results, thereby enhancing physician confidence in treatment choices.
- Future Outlook: With the FDA's approval, Agilent is poised to capture a larger market share in the future, potentially attracting more investor interest in its innovative capabilities and market potential within the biotechnology sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy A?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on A
Wall Street analysts forecast A stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 124.330
Low
160.00
Averages
171.67
High
180.00
Current: 124.330
Low
160.00
Averages
171.67
High
180.00
About A
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Honeywell Board Approves Aerospace Spin-Off
- Spin-Off Approval: Honeywell's Board of Directors has formally approved the spin-off of its Aerospace division, expected to be completed on June 29, 2026, marking a significant milestone in the company's portfolio transformation over the past three years aimed at enhancing the competitiveness of both independent entities.
- Stock Distribution Details: On June 29, 2026, Honeywell will distribute shares of Aerospace common stock to shareholders on a pro-rata basis, with one share of Aerospace stock for every two shares of Honeywell common stock held, thereby enhancing shareholder returns.
- Exchange Listing Arrangements: Aerospace common stock is expected to begin trading on Nasdaq on a
See More
Honeywell Announces Aerospace Spin-Off Plan
- Spin-Off Date Set: Honeywell's Board of Directors has established June 15, 2026, as the record date for the spin-off of its Aerospace business, with a distribution expected on June 29, 2026, at a ratio of one share of Aerospace stock for every two shares of Honeywell common stock, marking a significant restructuring step for the company.
- Independent Trading Launch: Aerospace common stock is set to begin trading on Nasdaq under the ticker symbol 'HONA' on June 29, 2026, providing Honeywell Aerospace with an independent capital market platform that enhances its competitive position in the aerospace sector.
- Reverse Stock Split: Honeywell also announced a 1-for-2 reverse stock split, expected to reduce the outstanding shares from approximately 634 million to about 317 million, aimed at improving earnings per share and optimizing capital structure to boost investor confidence.
- Tax Implications Clarified: The spin-off is expected to be tax-free for Honeywell shareholders for U.S. federal income tax purposes, except for cash received for fractional shares, which will help attract more investors to focus on the company's long-term value creation potential.
See More
FDA Expands Agilent's PD-L1 Test Indication for Keytruda Use
- Indication Expansion: The FDA has expanded the indication for Agilent's PD-L1 IHC 22C3 pharmDx test to include four new tumor types, such as esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction adenocarcinoma, enhancing the test's value in cancer treatment decision-making.
- Market Impact: This expansion allows the PD-L1 IHC 22C3 pharmDx test to assist more patients in accessing Merck's Keytruda (pembrolizumab) treatment, which is expected to boost Agilent's competitiveness in the cancer diagnostics market, particularly in the rapidly growing immunotherapy sector.
- Technical Platform: The test is performed on the Dako Omnis platform, integrating advanced detection technology that ensures accuracy and reliability of results, thereby enhancing physician confidence in treatment choices.
- Future Outlook: With the FDA's approval, Agilent is poised to capture a larger market share in the future, potentially attracting more investor interest in its innovative capabilities and market potential within the biotechnology sector.
See More
Agilent Partners with OpenAI and BCG to Accelerate AI Deployment
- Strategic Collaboration: Agilent has partnered with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence across its products, operations, and customer workflows, reflecting the company's ambition and commitment to execution in the AI domain.
- Innovation Drive: By integrating advanced AI capabilities, Agilent aims to enhance the intelligence of its products and services, with plans to significantly improve customer experience and accelerate its new product pipeline over the next six to twelve months.
- Competitive Advantage: This collaboration will enable Agilent to transform AI into a competitive advantage, shifting from pilot projects to scaled deployment, thereby redefining how value is created across the enterprise and enhancing decision-making support.
- Resource Integration: By combining Agilent's scientific expertise with OpenAI's AI research and BCG's large-scale transformation experience, the partnership aims to identify, build, and scale high-impact applied AI solutions, enhancing the overall innovation capacity of the enterprise.
See More
Agilent Receives FDA Approval for Expanded PD-L1 Testing
- Platform Expansion: Agilent announced FDA approval for the expanded use of PD-L1 IHC 22C3 pharmDx on the Dako Omnis platform, facilitating testing for patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric adenocarcinoma, thereby increasing access to KEYTRUDA® treatment for more patients.
- Workflow Optimization: This approval allows pathology laboratories to consolidate PD-L1 testing across multiple tumor types within a single Dako Omnis workflow, significantly enhancing automation and operational efficiency, which meets the laboratories' demand for standardized testing.
- Multi-Site Study Validation: Agilent conducted a multisite external platform performance comparison study that validated the concordance of PD-L1 IHC 22C3 pharmDx results across different staining platforms, ensuring reliability at appropriate CPS cutoffs, thus boosting confidence in clinical applications.
- Strategic Market Alignment: This expansion aligns with Agilent's strategic goals in the clinical diagnostics field, aiming to provide more convenient testing services that support clinicians in effectively identifying patients eligible for immunotherapy, further solidifying its leadership position in the biomarker testing market.
See More
Valuation Analysis of U.S. Healthcare Stocks
- High Valuation Companies: Among U.S. healthcare stocks with market caps over $10 billion, Agilent Technologies (A) stands out with a valuation grade of F, indicating its high valuation relative to peers, which may influence investor purchasing decisions.
- Valuation Scoring Mechanism: Seeking Alpha's valuation grades assess stocks based on a comprehensive set of metrics including P/E, PEG, and EV/Sales, providing crucial insights for investors regarding relative pricing within the sector.
- Other High Valuation Stocks: Companies like Danaher Corporation (DHR) and GE HealthCare Technologies (GEHC) also received an F valuation grade, highlighting the high valuation risks these firms face in the current market environment, prompting investors to reassess their portfolios.
- Market Dynamics: Despite Summit Therapeutics (SMMT) facing downward pressure following recent clinical data releases, the overall valuation landscape for healthcare stocks indicates a cautious investor sentiment towards high valuation stocks, potentially affecting future capital flows.
See More
Honeywell Board Approves Aerospace Spin-Off
- Spin-Off Approval: Honeywell's Board of Directors has formally approved the spin-off of its Aerospace division, expected to be completed on June 29, 2026, marking a significant milestone in the company's portfolio transformation over the past three years aimed at enhancing the competitiveness of both independent entities.
- Stock Distribution Details: On June 29, 2026, Honeywell will distribute shares of Aerospace common stock to shareholders on a pro-rata basis, with one share of Aerospace stock for every two shares of Honeywell common stock held, thereby enhancing shareholder returns.
- Exchange Listing Arrangements: Aerospace common stock is expected to begin trading on Nasdaq on a
See More
Honeywell Announces Aerospace Spin-Off Plan
- Spin-Off Date Set: Honeywell's Board of Directors has established June 15, 2026, as the record date for the spin-off of its Aerospace business, with a distribution expected on June 29, 2026, at a ratio of one share of Aerospace stock for every two shares of Honeywell common stock, marking a significant restructuring step for the company.
- Independent Trading Launch: Aerospace common stock is set to begin trading on Nasdaq under the ticker symbol 'HONA' on June 29, 2026, providing Honeywell Aerospace with an independent capital market platform that enhances its competitive position in the aerospace sector.
- Reverse Stock Split: Honeywell also announced a 1-for-2 reverse stock split, expected to reduce the outstanding shares from approximately 634 million to about 317 million, aimed at improving earnings per share and optimizing capital structure to boost investor confidence.
- Tax Implications Clarified: The spin-off is expected to be tax-free for Honeywell shareholders for U.S. federal income tax purposes, except for cash received for fractional shares, which will help attract more investors to focus on the company's long-term value creation potential.
See More
FDA Expands Agilent's PD-L1 Test Indication for Keytruda Use
- Indication Expansion: The FDA has expanded the indication for Agilent's PD-L1 IHC 22C3 pharmDx test to include four new tumor types, such as esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction adenocarcinoma, enhancing the test's value in cancer treatment decision-making.
- Market Impact: This expansion allows the PD-L1 IHC 22C3 pharmDx test to assist more patients in accessing Merck's Keytruda (pembrolizumab) treatment, which is expected to boost Agilent's competitiveness in the cancer diagnostics market, particularly in the rapidly growing immunotherapy sector.
- Technical Platform: The test is performed on the Dako Omnis platform, integrating advanced detection technology that ensures accuracy and reliability of results, thereby enhancing physician confidence in treatment choices.
- Future Outlook: With the FDA's approval, Agilent is poised to capture a larger market share in the future, potentially attracting more investor interest in its innovative capabilities and market potential within the biotechnology sector.
See More
Agilent Partners with OpenAI and BCG to Accelerate AI Deployment
- Strategic Collaboration: Agilent has partnered with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence across its products, operations, and customer workflows, reflecting the company's ambition and commitment to execution in the AI domain.
- Innovation Drive: By integrating advanced AI capabilities, Agilent aims to enhance the intelligence of its products and services, with plans to significantly improve customer experience and accelerate its new product pipeline over the next six to twelve months.
- Competitive Advantage: This collaboration will enable Agilent to transform AI into a competitive advantage, shifting from pilot projects to scaled deployment, thereby redefining how value is created across the enterprise and enhancing decision-making support.
- Resource Integration: By combining Agilent's scientific expertise with OpenAI's AI research and BCG's large-scale transformation experience, the partnership aims to identify, build, and scale high-impact applied AI solutions, enhancing the overall innovation capacity of the enterprise.
See More
Agilent Receives FDA Approval for Expanded PD-L1 Testing
- Platform Expansion: Agilent announced FDA approval for the expanded use of PD-L1 IHC 22C3 pharmDx on the Dako Omnis platform, facilitating testing for patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric adenocarcinoma, thereby increasing access to KEYTRUDA® treatment for more patients.
- Workflow Optimization: This approval allows pathology laboratories to consolidate PD-L1 testing across multiple tumor types within a single Dako Omnis workflow, significantly enhancing automation and operational efficiency, which meets the laboratories' demand for standardized testing.
- Multi-Site Study Validation: Agilent conducted a multisite external platform performance comparison study that validated the concordance of PD-L1 IHC 22C3 pharmDx results across different staining platforms, ensuring reliability at appropriate CPS cutoffs, thus boosting confidence in clinical applications.
- Strategic Market Alignment: This expansion aligns with Agilent's strategic goals in the clinical diagnostics field, aiming to provide more convenient testing services that support clinicians in effectively identifying patients eligible for immunotherapy, further solidifying its leadership position in the biomarker testing market.
See More
Valuation Analysis of U.S. Healthcare Stocks
- High Valuation Companies: Among U.S. healthcare stocks with market caps over $10 billion, Agilent Technologies (A) stands out with a valuation grade of F, indicating its high valuation relative to peers, which may influence investor purchasing decisions.
- Valuation Scoring Mechanism: Seeking Alpha's valuation grades assess stocks based on a comprehensive set of metrics including P/E, PEG, and EV/Sales, providing crucial insights for investors regarding relative pricing within the sector.
- Other High Valuation Stocks: Companies like Danaher Corporation (DHR) and GE HealthCare Technologies (GEHC) also received an F valuation grade, highlighting the high valuation risks these firms face in the current market environment, prompting investors to reassess their portfolios.
- Market Dynamics: Despite Summit Therapeutics (SMMT) facing downward pressure following recent clinical data releases, the overall valuation landscape for healthcare stocks indicates a cautious investor sentiment towards high valuation stocks, potentially affecting future capital flows.
See More
